乳腺癌治疗中新辅助内分泌治疗的现状与未来
The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment.
作者信息
Martí Covadonga, Sánchez-Méndez José Ignacio
机构信息
Breast Cancer Unit, Hospital Universitario La Paz, 28046 Madrid, Spain.
Gynaecology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.
出版信息
Cancers (Basel). 2021 May 21;13(11):2538. doi: 10.3390/cancers13112538.
Abstract
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor-positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre-surgical approach with chemotherapy (NCT) has become a common form of management for large, locally advanced, or high-risk tumors. However, a good response to NCT is not usually expected in ER+ tumors. Good results with primary ET, mainly in elderly women, have encouraged studies in other stages of life, and nowadays neoadjuvant endocrine treatment (NET) has become a useful approach to many ER+ breast cancers. The aim of this review is to provide an update on the current state of art regarding the present and the future role of NET.
摘要
内分泌治疗（ET）已成为雌激素受体阳性（ER+）乳腺癌的一种有效治疗方法，可降低复发率并提高生存率。术前化疗（NCT）已成为治疗大型、局部晚期或高危肿瘤的常见管理方式。然而，通常预计ER+肿瘤对NCT的反应不佳。主要在老年女性中进行的原发性ET取得的良好效果促使人们对其他年龄段进行研究，如今新辅助内分泌治疗（NET）已成为许多ER+乳腺癌的一种有效治疗方法。本综述的目的是提供关于NET当前现状以及其当前和未来作用的最新信息。
相似文献
1
The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment.乳腺癌治疗中新辅助内分泌治疗的现状与未来
Cancers (Basel). 2021 May 21;13(11):2538. doi: 10.3390/cancers13112538.
2
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.绝经前激素受体阳性、HER2 阴性、淋巴结阳性乳腺癌患者新辅助内分泌治疗与新辅助化疗的疗效比较。
Breast Cancer Res. 2020 May 27;22(1):54. doi: 10.1186/s13058-020-01288-5.
3
Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.在雌激素受体阳性、人表皮生长因子受体 2 阴性的乳腺癌患者中进行同期新辅助化疗和雌激素剥夺治疗（CBCSG-036）：一项随机、对照、多中心试验。
Cancer. 2019 Jul 1;125(13):2185-2193. doi: 10.1002/cncr.32057. Epub 2019 Mar 20.
4
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
5
Locoregional and Overall Recurrence After Neaodjuvant Endocrine Therapy Versus Chemotherapy in Postmenopausal Women With Estrogen Receptor+ HER2- Breast Cancer.绝经后雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者新辅助内分泌治疗与化疗后的局部区域复发和总复发情况
Am J Clin Oncol. 2017 Oct;40(5):490-497. doi: 10.1097/COC.0000000000000194.
6
Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.新辅助化疗后乳腺癌中 miR-18a 表达的临床和生物学影响。
Cell Oncol (Dordr). 2019 Oct;42(5):627-644. doi: 10.1007/s13402-019-00450-2. Epub 2019 May 21.
7
A Randomized Feasibility Study of F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.一项关于F-氟雌二醇PET预测富含雌激素受体的绝经后乳腺癌新辅助治疗病理反应的随机可行性研究。
J Nucl Med. 2017 Apr;58(4):563-568. doi: 10.2967/jnumed.116.178368. Epub 2016 Sep 29.
8
Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.对于接受新辅助芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者，突变并非内分泌抵抗的常见机制。
Front Oncol. 2020 Apr 3;10:342. doi: 10.3389/fonc.2020.00342. eCollection 2020.
9
Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.新辅助内分泌治疗与新辅助化疗治疗 ER 阳性乳腺癌的疗效：来自前瞻性机构数据库的结果。
Clin Breast Cancer. 2019 Dec;19(6):e683-e689. doi: 10.1016/j.clbc.2019.05.020. Epub 2019 Jun 11.
10
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.新辅助内分泌治疗：雌激素受体阳性乳腺癌的一种潜在策略。
World J Clin Cases. 2019 Aug 6;7(15):1937-1953. doi: 10.12998/wjcc.v7.i15.1937.
引用本文的文献
1
Early Predictive Markers and Histopathological Response to Neoadjuvant Endocrine Therapy in Postmenopausal Patients with HR+/HER2- Early Breast Cancer.绝经后HR+/HER2-早期乳腺癌患者新辅助内分泌治疗的早期预测标志物及组织病理学反应
Cancers (Basel). 2025 Jul 12;17(14):2319. doi: 10.3390/cancers17142319.
2
Dalpiciclib plus aromatase inhibitor versus neoadjuvant chemotherapy for ER-positive, HER2-negative breast cancer.达尔西利联合芳香化酶抑制剂与新辅助化疗治疗激素受体阳性、人表皮生长因子受体2阴性乳腺癌的比较
Front Oncol. 2025 Apr 30;15:1566146. doi: 10.3389/fonc.2025.1566146. eCollection 2025.
3
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.图昔替尼加多西他赛联合依维莫司作为新辅助治疗激素受体阳性、人表皮生长因子受体 2 阴性早期乳腺癌的研究
Oncologist. 2024 Jun 3;29(6):e763-e770. doi: 10.1093/oncolo/oyae033.
4
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.早期雌激素受体阳性乳腺癌新辅助内分泌治疗后肿瘤反应评估方法的前瞻性研究。
Breast Cancer Res. 2024 Jan 3;26(1):3. doi: 10.1186/s13058-023-01756-8.
5
Unveiling the Role of Hormonal Imbalance in Breast Cancer Development: A Comprehensive Review.揭示激素失衡在乳腺癌发生中的作用：一项综述
Cureus. 2023 Jul 11;15(7):e41737. doi: 10.7759/cureus.41737. eCollection 2023 Jul.
6
Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer.雌激素受体阳性乳腺癌新辅助内分泌治疗或化疗后的生物标志物改变
Life (Basel). 2022 Dec 27;13(1):74. doi: 10.3390/life13010074.
7
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.新辅助内分泌治疗后的局部区域复发：来自 ACOSOG Z1031（Alliance）的数据，这是一项针对绝经后雌激素受体阳性临床 2 期或 3 期乳腺癌患者的新辅助比较研究，比较了来曲唑、阿那曲唑和依西美坦。
Ann Surg Oncol. 2023 Apr;30(4):2111-2118. doi: 10.1245/s10434-022-12972-5. Epub 2023 Jan 18.
8
Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.评估术前腋窝淋巴结疾病负担：新辅助内分泌治疗前后局部晚期乳腺癌的乳腺 MRI。
BMC Cancer. 2022 Jun 25;22(1):702. doi: 10.1186/s12885-022-09813-9.
9
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).评估内分泌治疗敏感指数（SET2,3）对新辅助内分泌治疗反应和长期乳腺癌患者结局的影响（Alliance Z1031）。
Clin Cancer Res. 2022 Aug 2;28(15):3287-3295. doi: 10.1158/1078-0432.CCR-22-0068.
10
The Clinical Impact of Neoadjuvant Endocrine Treatment on Luminal-like Breast Cancers and Its Prognostic Significance: Results from a Single-Institution Prospective Cohort Study.新辅助内分泌治疗对腔面样乳腺癌的临床影响及其预后意义：单中心前瞻性队列研究结果。
Curr Oncol. 2022 Mar 23;29(4):2199-2210. doi: 10.3390/curroncol29040179.
本文引用的文献
1
Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer.ER 阳性/HER2 阴性乳腺癌新辅助内分泌治疗的真实世界数据。
Breast Cancer Res Treat. 2021 Apr;186(3):753-760. doi: 10.1007/s10549-020-06076-5. Epub 2021 Feb 4.
2
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.绝经后激素敏感型早期乳腺癌（POETIC）患者围手术期内分泌治疗后 Ki67 的长期预后价值：一项开放标签、多中心、平行组、随机、III 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1443-1454. doi: 10.1016/S1470-2045(20)30458-7.
3
Endocrine Therapy in Early Breast Cancer.早期乳腺癌的内分泌治疗
Breast Care (Basel). 2020 Aug;15(4):337-346. doi: 10.1159/000509362. Epub 2020 Jul 21.
4
Axillary Response in Patients Undergoing Neoadjuvant Endocrine Treatment for Node-Positive Breast Cancer: Systematic Literature Review and NCDB Analysis.接受新辅助内分泌治疗的淋巴结阳性乳腺癌患者的腋窝反应：系统文献回顾和 NCDB 分析。
Ann Surg Oncol. 2020 Nov;27(12):4669-4677. doi: 10.1245/s10434-020-08905-9. Epub 2020 Sep 9.
5
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer.用于乳腺癌的PET/CT和PET/MRI分子成像方法的进展与未来趋势
Front Oncol. 2020 Aug 12;10:1301. doi: 10.3389/fonc.2020.01301. eCollection 2020.
6
Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.新辅助内分泌治疗激素受体阳性乳腺癌的腋窝管理。
Ann Surg Oncol. 2021 Mar;28(3):1358-1367. doi: 10.1245/s10434-020-09073-6. Epub 2020 Aug 31.
7
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?新辅助内分泌治疗（NET）在降期腋窝和实现保乳手术方面的效果如何？
Ann Surg Oncol. 2020 Nov;27(12):4702-4710. doi: 10.1245/s10434-020-08888-7. Epub 2020 Aug 24.
8
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.新辅助内分泌治疗后激素受体阳性乳腺癌残留淋巴结疾病的预后意义
NPJ Breast Cancer. 2020 Aug 13;6:35. doi: 10.1038/s41523-020-00177-6. eCollection 2020.
9
Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments.接受新辅助内分泌治疗患者的乳腺MRI准确性：综合影像分析及其与临床和病理评估的相关性
Breast Cancer Res Treat. 2020 Nov;184(2):407-420. doi: 10.1007/s10549-020-05852-7. Epub 2020 Aug 12.
10
Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.新辅助内分泌治疗前后乳腺 MRI 对侧实质强化与术前内分泌预后指数的关系。
Eur Radiol. 2020 Dec;30(12):6740-6748. doi: 10.1007/s00330-020-07058-3. Epub 2020 Jul 20.
Zotero 插件